Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... In today,s fast changing healthcare environment, ... positive health outcomes, improve profitability and enhance their ... in their communities. At ThoughtSpot 2015, Good ... announced a new set of innovative capabilities that ... help independent pharmacies endure the industry,s most pressing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 ... insights on the global resorcinol industry. The report highlights the various growth prospects ... scenarios and analysis of primary and secondary inputs from the existing players of ...
(Date:7/31/2015)... , July 31, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has filed ... Securities and Exchange Commission. The filed Form 20-F includes ... 31, 2015. The Form 20-F can be accessed by ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... January 24, 2012 SPO Medical Inc. ... microprocessor technologies for use in portable monitoring devices, announced ... product and revenue generation strategy for fiscal 2012 primarily ... a new range of consumer wellness devices. ...
... Pennsylvania research team have shown that they can prevent, or ... XLRP, in dogs. The disease in humans and dogs ... in early, severe and progressive vision loss. It is one ... man. "Every single abnormal feature that defines the ...
... thinnest material known to science. The nanomaterial is so thin, ... Engineering researchers at Rensselaer Polytechnic Institute and Rice University coated ... of graphene, and then placed a drop of water on ... have virtually no impact on the manner in which water ...
Cached Biology Technology:SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3Nature Materials study: Graphene 'invisible' to water 2Nature Materials study: Graphene 'invisible' to water 3Nature Materials study: Graphene 'invisible' to water 4
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... new way to study the role of a critical ... schizophrenia, and alcohol addiction has been developed by a ... professor of biology at Penn State University. The new ... structure through which a nerve cell send signals to ...
... display or a solar panel, any conductive overlay had better ... oxide (ITO) for the job, but a high-tech material,s properties ... cheap and easy to manufacture as possible. In a new ... best-ever transparency and conductivity performance for an ITO made using ...
... 2012The global market value of Alzheimer,s disease therapeutics could soar ... actually change the course of the disease, reports Genetic ... is valued at $3 to $4 billion, shared among drugs ... do not alter the underlying disease, according to a ...
Cached Biology News:New model synapse could shed light on disorders such as epilepsy and anxiety 2New model synapse could shed light on disorders such as epilepsy and anxiety 3Chemists advance clear conductive thin films 2GEN reports on recent progress in Alzheimer's research 2
... the things youll be telling others after you ... Erica Golemis, One look at the table of ... in protein interaction will tell you immediately that ... part of your personal protein chemistry library. You ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... capillary electrophoresis, real-time PCR assays and bandshift ...
... Environment 2) Dot plot, Contour plot, ... Compensation 4) Cell Cycle 5) ... Intelligent batch generation of graphs and statistics ... drag-and-drop operations to perform complex batch analyses ...
Synonym: modified Grace's Insect medium...
Biology Products: